Cipla expects record 24 per cent Ebitda margin in FY24

"We enter reverse seasonalist in our India business. The fourth quarter has always been the lowest, so that impacts our margins," Umang Vohra MD and Global CEO of Cipla, said in a post-earnings media call.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news